Recent Updates — SNYNF

Sanofi reported third-quarter net sales of €14,444 million, a 14.3% increase at constant exchange rates (CER), driven by double-digit growth in pharma launches and Dupixent sales reaching €5.7 billion. Business earnings per share rose 19.6% to €3.55 at CER, supported by cost discipline and operating leverage. The company upgraded its full-year 2026 guidance, now expecting low-teens sales growth and mid-teens business EPS growth at CER. Additionally, Sanofi announced an expanded collaboration with Regeneron involving a $1 billion upfront payment for new immunology assets and a strategic partnership with Cheplapharm to divest mature medicines. The company operates in the pharmaceutical industry, developing and marketing prescription drugs, vaccines, and consumer health products.

The European Commission approved an extension of the indication for MenQuadfi to include infants from six weeks of age against invasive meningococcal disease, expanding its previous approval for individuals aged 12 months and older. This regulatory milestone follows a positive opinion from the Committee for Medicinal Products for Human Use on June 25, 2026, and is supported by immunogenicity data from the MET58 pivotal clinical study involving over 6,000 infants across 11 countries. The approval allows for new dosing regimens aligned with routine infant immunization schedules, including a 2+1 schedule for standard risk and a 3+1 schedule for high-risk exposure to serogroup A. Sanofi is an R&D driven biopharmaceutical company focused on developing vaccines and medicines to improve public health outcomes globally.

Sanofi reported Q2 2026 net sales of €11,597 million, a 17.8% increase at constant exchange rates (CER), driven by a 48.3% surge in Pharma launches to €1.3 billion and Dupixent sales rising 37.6% to €5.2 billion. Business EPS grew 33.3% at CER to €2.09, while IFRS EPS was €0.29 due to non-cash amortization and impairment charges totaling over €2 billion. The company upgraded its full-year 2026 guidance, now expecting sales growth of around 10% at CER with business EPS growing slightly faster than sales. Pipeline updates included seven regulatory approvals, two positive Phase 3 readouts for Nexviazyme and amlitelimab, and the discontinuation of development programs for amlitelimab, itepekimab, and balinatunfib. Sanofi operates in the pharmaceutical industry.